New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
You may also be interested in...
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.
Using the cancer drug off-label to treat wet AMD has been controversial.
Santhera Pharmaceuticals’ vamorolone for treating Duchenne muscular dystrophy is among the latest medicines that have been submitted for review for potential pan-EU approval.